Natera has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company’s Signatera customized circulating tumor DNA assay for recurrence monitoring of kidney cancer. The study will analyze biological specimens collected and banked from 49 patients diagnosed with kidney cancer-including a group whose cancer recurred and a group that did not recur after three years or more. The study will use Natera’s proprietary customized assay and next-generation sequencing-based technology to determine whether Signatera can be used to distinguish between the recurring and non-recurring kidney cancer cases. The study will be led by Philip Abbosh, M.D., Ph.D., assistant professor, Molecular Therapeutics Program, Fox Chase Cancer Center.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.